Tarsus Pharmaceuticals (NASDAQ:TARS) reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage investigational Stargardt disease therapy gildeuretinol, also known as ALK-001, to its pipeline. Tarsus said those toxic byproducts contribute to retinal cell damage in Stargardt disease, an inherited retinal disorder that can cause progressive central-vision loss and blindness. Chief Operating Officer Sesha Neervannan said Stargardt disease affects children and young adults and currently has no FDA-approved therapies. Tarsus maintained guidance for gross margin of approximately 93% and selling, general and administrative expenses of $545 million to $565 million for 2026. About Tarsus Pharmaceuticals (NASDAQ:TARS)Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface.